Sign up for Breaking News Email Alerts

  • Cash, Catalysts And Charisma Should Drive Neuralstem

By Jason Napodano, CFA, PropThink, November 4, 2013

A comprehensive overview of the year ahead for Neuralstem’s ongoing and upcoming cell therapy and neurogenic small molecule clinical trials.

View Article

Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.

Privacy and Terms ©Neuralstem, Inc. 2014

FORBES' forward-looking “Pharma & Healthcare” feature quotes President/CEO Richard Garr extensively, on the differentiation and commercialization aspects of Neuralstem’s proprietary cell technology. | November 2013
FOX Medical Team's Beth Galvin continues her NSI-566/ALS coverage at Emory with a patient’s perspective segment. Phase I patients, Ted Harada and John Conley, are featured. | 11.20.13
Bethesda Magazine feature provides rich insights on Neuralstem’s “potential wonder drug aimed specifically at rebuilding the hippocampus”: NSI-189. | November-December 2013
Practical Neurology interviews Chairman and CSO Dr. Karl Johe and Principal Investigator Dr. Eva Feldman about the NSI-566/ALS trials in this article, entitled “Decreasing Progression, Increasing Function.” | October 2013
FOX News Detroit walks with NSI-566/ALS Phase I patient Ted Harada and P.I. Dr. Eva Feldman in a “Health Works” feature on the eve of the Phase II trial. | 8.28.13
Bioscience Technology ALS P.I. Dr. Eva Feldman and Neuralstem’s President/CEO Richard Garr in a feature that explores data from six extraordinary ALS responders – “as rare as a red wolf.” | 5.30.13
MIT's Technology Review reports on CELL SCI research showing “paralyzed rats walk again after stem cell transplant” of NSI-566, suggesting hope for treatment of spinal cord injury. | 9.13.12